Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Andromeda Biotech Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT01898286
- Locations
- 🇺🇸
Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States
🇺🇸Atlanta Diabetes associates, Atlanta, Georgia, United States
🇺🇸Henry Ford Medical Centers - New Center One, Detroit, Michigan, United States
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Andromeda Biotech Ltd.
- Target Recruit Count
- 475
- Registration Number
- NCT01103284
- Locations
- 🇺🇸
AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States
🇺🇸Sutter Gold Medical Foundation, Modesto, California, United States
🇺🇸San Diego Clinical Trials, San Diego, California, United States
Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Andromeda Biotech Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT00644501
- Locations
- 🇮🇱
Diabetic Unit, Hadassah Medical Center, Jerusalem, Israel
🇮🇱Schneider Children's Medical Centre, Petach Tikva, Israel
🇮🇱Wolfson Medical Centre, Holon, Israel
Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Andromeda Biotech Ltd.
- Target Recruit Count
- 457
- Registration Number
- NCT00615264
- Locations
- 🇨🇿
Faculty hospital Motol., Prague, Czech Republic
🇮🇱Schneider Children's Medical Centre, Petach Tikva, Israel
🇮🇹Universita' degli Studi di Bari, Bari, Italy
© Copyright 2025. All Rights Reserved by MedPath